Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

206.96 +2.21 (+1.08%)

Streaming Delayed Price Updated: 3:26 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now ↗

October 18, 2024

These stocks could deliver big over the long term.

Via The Motley Fool

This Magnificent Dividend Stock Is as Healthy as It Gets ↗

October 17, 2024

Johnson & Johnson's latest financial checkup shows it's still in excellent health.

Via The Motley Fool

Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say ↗

October 16, 2024

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated 2024 guidance reflects performance improvement but includes costs tied to...

Via Benzinga

Johnson & Johnson Stock: Setting the Stage for 2025 Highs

October 16, 2024

Healthcare giant and Dividend Aristocrat Johnson & Johnson is on track to hit new highs in 2025 and may sustain its rally well into 2026.

Via MarketBeat

Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold? ↗

October 16, 2024

Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.

Via The Motley Fool

Johnson & Johnson’s Medtech Segment Shines With Impressive Q3 Growth ↗

October 15, 2024

Johnson & Johnson's third-quarter performance exceeded expectations, with adjusted EPS of $2.42 against an expected $2.19.

Via Talk Markets

Why NYSE:JNJ is a Top Pick for Dividend Investors. ↗

October 15, 2024

Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics.

Via Chartmill

This Is What Whales Are Betting On Johnson & Johnson ↗

October 14, 2024

Via Benzinga

Are JNJ’s Mergers And Acquisitions Weighing Down Company’s Performance? ↗

October 15, 2024

In the last two years, JNJ has invested over $30 billion in acquisitions.

Via Talk Markets

Cancer Drugs Propel J&J Beyond Wall Street Estimates ↗

October 15, 2024

On Tuesday, Johnson & Johnson (NYSE: JNJ) posted better-than-expected third quarter sales and adjusted profit. Fueled by strong results, Johnson & Johnson raised its full year profit and sales...

Via Benzinga

Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript ↗

October 15, 2024

JNJ earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results ↗

October 15, 2024

Via Benzinga

Chipmaker Stocks Sink On ASML Earnings Leak, Oil Eyes Worst 1-Day Drop This Year, Small Caps Rally: What's Driving Markets Tuesday? ↗

October 15, 2024

A wave of market-relevant news fueled an active trading session on Wall Street Tuesday, with large-cap indices falling due to sharp declines in tech and energy stocks, while small-caps outperformed,...

Via Benzinga

Google Goes Nuclear For AI Power, Israeli Restraint Impacts Stocks, Gold, And Oil ↗

October 15, 2024

To gain an edge, this is what you need to know today.

Via Benzinga

Topics Artificial Intelligence

Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition ↗

October 15, 2024

Johnson & Johnson reported third-quarter earnings with adjusted EPS of $2.42, surpassing expectations. Sales rose 5.2% to $22.47B. J&J updated its 2024 adjusted EPS guidance, lowering it slightly to...

Via Benzinga

Johnson & Johnson Earnings Top; Dow Giant Works Toward Buy Point ↗

October 15, 2024

J&J stock edged higher early Tuesday.

Via Investor's Business Daily

Topics Stocks

Wall Street On Edge As Nasdaq Nears Record High, Oil Prices Plummet: Strategist Says There's Opportunity If Resilience Continues ↗

October 15, 2024

Wall Street mood has become circumspect as traders gear up to receive a slew of earnings reports this week amid the market’s record run. The Nasdaq Composite has been a laggard among the major averages...

Via Benzinga

Topics Stocks

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024

October 15, 2024

From Johnson & Johnson

Via Business Wire

Johnson & Johnson Reports Q3 2024 Results

October 15, 2024

From Johnson & Johnson

Via Business Wire

Jim Cramer Says Earnings Season Will Fuel Market's Record Run, But Warns Of This 'Horrendous' Headwind That Could Apply Brakes To Rally ↗

October 15, 2024

The stock market has been on a two-year strong run and the extended rally has begun to stir valuation concerns.

Via Benzinga

Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce ↗

October 14, 2024

Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.

Via Talk Markets

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

October 14, 2024

Via Benzinga

More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug ↗

October 14, 2024

On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s...

Via Benzinga

Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals ↗

October 14, 2024

JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's stagnant performance.

Via Benzinga

Best Pharma Stocks for Long-Term Investors: Growth and Dividends

October 14, 2024

Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive.

Via MarketBeat

Columbus Day: Is Stock Market Open Today? ↗

October 14, 2024

Investors should brace for a busy week with earnings reports from major companies.

Via Benzinga

Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top

October 13, 2024

Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there.

Via MarketBeat

All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year ↗

October 13, 2024

Target, PepsiCo, and Kenvue have high yields and inexpensive valuations.

Via The Motley Fool

Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12 ↗

October 12, 2024

Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock.

Via Talk Markets

Stocks Extend Weekly Win Streaks To 5 ↗

October 11, 2024

Wall Street enjoyed healthy gains to close out both the day and week.

Via Talk Markets

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions